Eli Lilly Company News

Vasa Therapeutics to Use Eli Lilly AI Platform in Drug Discovery Collaboration - Contract Pharma

Vasa Therapeutics to Use Eli Lilly AI Platform in Drug Discovery Collaboration Contract Pharma

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates - Business Wire

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates Business Wire

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - Eli Lilly

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly

Eli Lilly To Acquire CrossBridge Bio To Advance Dual-Payload Cancer Drugs - Stocktwits

Eli Lilly To Acquire CrossBridge Bio To Advance Dual-Payload Cancer Drugs Stocktwits

Eli Lilly to buy Houston cancer-fighting startup CrossBridge Bio in $300M deal - The Business Journals

Eli Lilly to buy Houston cancer-fighting startup CrossBridge Bio in $300M deal The Business Journals

Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill - Yahoo Finance

Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill Yahoo Finance

Eli Lilly & Co. stock (US5324571083): Is its obesity drug dominance strong enough to unlock new upsi - AD HOC NEWS

Eli Lilly & Co. stock (US5324571083): Is its obesity drug dominance strong enough to unlock new upsi AD HOC NEWS

Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3B deal - statnews.com

Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3B deal statnews.com

CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly - ZAWYA

CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly ZAWYA

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market - CNBC

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market CNBC

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk - BioPharma Dive

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk BioPharma Dive

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Eli Lilly and Company - Eli Lilly

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Eli Lilly and Company Eli Lilly

Jackson Square Capital LLC Boosts Eli Lilly and Company Holdings - National Today

Jackson Square Capital LLC Boosts Eli Lilly and Company Holdings National Today

FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity - AP News

FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity AP News

Race for AI-developed drugs heats up: Wegovy-maker Novo Nordisk ties up with OpenAI after rival Eli Lilly seals deal - Mint

Race for AI-developed drugs heats up: Wegovy-maker Novo Nordisk ties up with OpenAI after rival Eli Lilly seals deal Mint

Eli Lilly and the ‘societal obligation’ of GLP-1s - statnews.com

Eli Lilly and the ‘societal obligation’ of GLP-1s statnews.com

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” - Yahoo Finance

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” Yahoo Finance

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes | Eli Lilly and Company - Eli Lilly

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes | Eli Lilly and Company Eli Lilly

Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk - statnews.com

Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk statnews.com

Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why - Yahoo Finance

Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why Yahoo Finance

FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly - NBC News

FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly NBC News

Eli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial - statnews.com

Eli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial statnews.com

Eli Lilly & Co. stock (US5324571083): Is obesity drug dominance strong enough to unlock new upside? - AD HOC NEWS

Eli Lilly & Co. stock (US5324571083): Is obesity drug dominance strong enough to unlock new upside? AD HOC NEWS

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility - Eli Lilly

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility Eli Lilly

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market - CNBC

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market CNBC

Eli Lilly Just Delivered Great News for Investors -- and It Goes Beyond Weight-Loss Drugs - Yahoo Finance

Eli Lilly Just Delivered Great News for Investors -- and It Goes Beyond Weight-Loss Drugs Yahoo Finance

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance - Eli Lilly

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance Eli Lilly

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet Reuters

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI | Eli Lilly and Company - Eli Lilly

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI | Eli Lilly and Company Eli Lilly

Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company - Eli Lilly

Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company Eli Lilly

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company - Eli Lilly

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company Eli Lilly

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - Eli Lilly

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 Eli Lilly

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients - Eli Lilly

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients Eli Lilly

Why Eli Lilly Stock Just Dropped - Yahoo Finance

Why Eli Lilly Stock Just Dropped Yahoo Finance

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company - Eli Lilly

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company Eli Lilly

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company - Eli Lilly

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company Eli Lilly